Biomica is a clinical-stage biopharmaceutical company that focuses on developing microbiome-based therapeutics aimed at treating cancer, immune-mediated, and infectious diseases. The company employs a unique approach that emphasizes understanding the functional elements of the microbiome, allowing for the selection of a minimal number of microbial strains to maximize therapeutic efficacy while minimizing adverse effects. Biomica's drug candidates are developed using their proprietary PRISM platform, which integrates advanced artificial intelligence and big data analytics with metagenomics sequencing. This enables the company to gain deep insights into the microbiome's complex interactions with the human host, facilitating the design of innovative therapeutic solutions.

The company’s pipeline includes several promising drug candidates, such as BMC128, BMC333, and BMC426, which are designed to address various conditions, including immuno-oncology, inflammatory bowel diseases, and irritable bowel syndrome. Biomica's approach to drug design is characterized by its focus on rationally designed live bacterial products (LBPs) that restore microbial diversity and functionality. Additionally, Biomica is advancing small-molecule drug candidates targeting antibiotic-resistant infections, such as Clostridioides difficile and MRSA, utilizing their microbiome therapeutics platform to develop selective treatments that preserve the patient's beneficial gut microbiota.

Israel

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

Cancer

Digestive System Diseases

Immune System Diseases

Infectious Diseases

Biomica

Solid tumor/s

BMC128

Biologics

Inflammatory bowel disease

BMC333

Irritable bowel syndrome

BMC426

Clostridioides difficile infection

BMC202

Small Molecule Pharmaceuticals

Artificial Intelligence

Immuno-Oncology

Microbiome

Therapeutic

Biomica

Company Details